TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group

Charlotte Levin Tykjær  Jørgensen; Christina Annette Bjerre; Bent Laursen Ejlertsen; Karsten D. Bjerre; Eva Balslev; Annette Bartels; Nils Brünner; Dorte L. Nielsen

doi:10.1186/1471-2407-14-360

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group

Charlotte Levin Tykjær Jørgensen, Christina Annette Bjerre, Bent Laursen Ejlertsen, Karsten D. Bjerre, Eva Balslev, Annette Bartels, Nils Brünner, Dorte L. Nielsen

Research output: Contribution to journal › Journal article › Research › peer-review

6 Citations (Scopus)

911 Downloads (Pure)

Original language	English
Article number	360
Journal	B M C Cancer
Volume	14
Number of pages	14
ISSN	1471-2407
DOIs	https://doi.org/10.1186/1471-2407-14-360
Publication status	Published - 2014

Keywords

TIMP-1
Gemcitabine
Docetaxel
Breast cancer
Prediction
Prognosis

Access to Document

10.1186/1471-2407-14-360

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative groupFinal published version, 618 KB

Cite this

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer : results from a randomized phase III trial from the Danish breast cancer cooperative group. / Jørgensen, Charlotte Levin Tykjær; Bjerre, Christina Annette; Ejlertsen, Bent Laursen; Bjerre, Karsten D.; Balslev, Eva; Bartels, Annette; Brünner, Nils; Nielsen, Dorte L.

In: B M C Cancer, Vol. 14, 360, 2014.

Research output: Contribution to journal › Journal article › Research › peer-review

Jørgensen, Charlotte Levin Tykjær ; Bjerre, Christina Annette ; Ejlertsen, Bent Laursen ; Bjerre, Karsten D. ; Balslev, Eva ; Bartels, Annette ; Brünner, Nils ; Nielsen, Dorte L. / TIMP-1 and responsiveness to gemcitabine in advanced breast cancer : results from a randomized phase III trial from the Danish breast cancer cooperative group. In: B M C Cancer. 2014 ; Vol. 14.

@article{07ba8e8fd6e74bc69030267929e2173d,

title = "TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group",

keywords = "TIMP-1, Gemcitabine, Docetaxel, Breast cancer, Prediction, Prognosis",

author = "J{\o}rgensen, {Charlotte Levin Tykj{\ae}r} and Bjerre, {Christina Annette} and Ejlertsen, {Bent Laursen} and Bjerre, {Karsten D.} and Eva Balslev and Annette Bartels and Nils Br{\"u}nner and Nielsen, {Dorte L.}",

year = "2014",

doi = "10.1186/1471-2407-14-360",

language = "English",

volume = "14",

journal = "B M C Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - TIMP-1 and responsiveness to gemcitabine in advanced breast cancer

T2 - results from a randomized phase III trial from the Danish breast cancer cooperative group

AU - Jørgensen, Charlotte Levin Tykjær

AU - Bjerre, Christina Annette

AU - Ejlertsen, Bent Laursen

AU - Bjerre, Karsten D.

AU - Balslev, Eva

AU - Bartels, Annette

AU - Brünner, Nils

AU - Nielsen, Dorte L.

PY - 2014

Y1 - 2014

KW - TIMP-1

KW - Gemcitabine

KW - Docetaxel

KW - Breast cancer

KW - Prediction

KW - Prognosis

U2 - 10.1186/1471-2407-14-360

DO - 10.1186/1471-2407-14-360

M3 - Journal article

C2 - 24884504

VL - 14

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

M1 - 360

ER -